Synergistic Inhibitory Effect of Hyperbaric Oxygen Combined with Sorafenib on Hepatoma Cells
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synergistic Inhibitory Effect of Hyperbaric Oxygen Combined with Sorafenib on Hepatoma Cells
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 6, Pages e100814
Publisher
Public Library of Science (PLoS)
Online
2014-06-24
DOI
10.1371/journal.pone.0100814
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sorafenib: from literature to clinical practice
- (2013) V. Di Marco et al. ANNALS OF ONCOLOGY
- Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma
- (2013) R. Wei et al. CLINICAL CANCER RESEARCH
- Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma
- (2013) Yingjian Liang et al. HEPATOLOGY
- Hyperbaric oxygen and cancer: more complex than we expected
- (2013) Liu Wenwu et al. Targeted Oncology
- In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma
- (2012) Alex Y. Chang et al. ANTI-CANCER DRUGS
- Sorafenib Inhibits Hypoxia-Inducible Factor-1 Synthesis: Implications for Antiangiogenic Activity in Hepatocellular Carcinoma
- (2012) L.-p. Liu et al. CLINICAL CANCER RESEARCH
- Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
- (2012) G. Ranieri et al. CURRENT MEDICINAL CHEMISTRY
- Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice
- (2012) Giovan Giuseppe Di Costanzo et al. DIGESTIVE AND LIVER DISEASE
- Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation
- (2012) Claudio Zavaglia et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Comprehensive Review of Hyperbaric Oxygen Therapy
- (2012) Seyed Amir Danesh-Sani et al. JOURNAL OF CRANIOFACIAL SURGERY
- Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma
- (2012) Masahito Nakano et al. ONCOLOGY
- Hyperbaric oxygen therapy and cancer—a review
- (2012) Ingrid Moen et al. Targeted Oncology
- Hyperbaric Oxygen Therapy for Radiation Cystitis in Patients with Prostate Cancer: A Long-Term Follow-Up Study
- (2012) Teruhiro Nakada et al. UROLOGIA INTERNATIONALIS
- Vasculogenic stem cell mobilization and wound recruitment in diabetic patients: Increased cell number and intracellular regulatory protein content associated with hyperbaric oxygen therapy
- (2011) Stephen R. Thom et al. WOUND REPAIR AND REGENERATION
- Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials
- (2010) Tao Zhang et al. ANTI-CANCER DRUGS
- Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
- (2010) Chih-Hung Hsu et al. JOURNAL OF HEPATOLOGY
- Hyperbaric oxygen therapy. Part 2: application in disease
- (2010) Melissa L. Edwards JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE
- Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells
- (2010) S. Huang et al. MOLECULAR CANCER THERAPEUTICS
- Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: Preliminary results
- (2009) Takayuki Ohguri et al. INTERNATIONAL JOURNAL OF HYPERTHERMIA
- Anchorage-independent cell growth signature identifies tumors with metastatic potential
- (2009) S Mori et al. ONCOGENE
- Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma
- (2009) R. C. Kane et al. ONCOLOGIST
- Sorafenib for the treatment of hepatocellular carcinoma across geographic regions
- (2009) Chiun Hsu et al. Expert Review of Clinical Pharmacology
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search